PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment

PRECISION is an initiative from the Belgian Society of Medical Oncology (BSMO) in collaboration with several stakeholders, encompassing four programs that aim to boost genomic and clinical knowledge with the ultimate goal to offer patients with metastatic solid tumors molecularly guided treatments....

Descripción completa

Detalles Bibliográficos
Autores principales: Thouvenin, J., Van Marcke, C., Decoster, L., Raicevic, G., Punie, K., Vandenbulcke, M., Salgado, R., Van Valckenborgh, E., Maes, B., Joris, S., Steichel, D. Vander, Vranken, K., Jacobs, S., Dedeurwaerdere, F., Martens, G., Devos, H., Duhoux, F.P., Rasschaert, M., Pauwels, P., Geboes, K., Collignon, J., Tejpar, S., Canon, J.-L., Peeters, M., Rutten, A., Van de Mooter, T., Vermeij, J., Schrijvers, D., Demey, W., Lybaert, W., Van Huysse, J., Mebis, J., Awada, A., Claes, K.B.M., Hebrant, A., Van der Meulen, J., Delafontaine, B., Bempt, I. Vanden, Maetens, J., de Hemptinne, M., Rottey, S., Aftimos, P., De Grève, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434164/
https://www.ncbi.nlm.nih.gov/pubmed/35970014
http://dx.doi.org/10.1016/j.esmoop.2022.100524
Descripción
Sumario:PRECISION is an initiative from the Belgian Society of Medical Oncology (BSMO) in collaboration with several stakeholders, encompassing four programs that aim to boost genomic and clinical knowledge with the ultimate goal to offer patients with metastatic solid tumors molecularly guided treatments. The PRECISION 1 study has led to the creation of a clinico-genomic database. The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) and GeNeo studies will increase the number of patients with advanced cancer that have comprehensive genotyping of their cancer. The PRECISION 2 project consists of investigator-initiated phase II studies aiming to provide access to a targeted drug for patients whose tumors harbor actionable mutations in case the matched drug is not available through reimbursement or clinical trials in Belgium.

Ejemplares similares